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Gleich’s syndrome (GS) is characterized by recurrent episodes of angioedema, increase 
in body weight, fever, hypereosinophilia, and elevated serum IgM. The exact etiology 
remains unclear. Currently, the only treatment strategy is the administration of high dose 
of steroids during the acute phases. We report the case of a 37-year-old man suffering 
from GS with recurrent episodes of angioedema, fever, hypereosinophilia [6,000/
mm3 (45%)], and high eosinophil cationic protein (ECP) (>200 μg/l), treated with oral 
steroids during the acute phase (prednisone 50–75 mg/day), the dose of maintenance 
being 25 mg/day. No monoclonal components were identified, and genetic tests exclude 
mutations including Bcr/Abl, JAK2 V617F, c-KIT D816V, and FIP1L1-PDGFRA. Using 
Luminex technology, we observed higher serum levels of interleukin (IL)-5, CCL2, and 
CCL11 during the acute exacerbations in comparison with the clinical remission phases 
though CCL11 did not achieve statistical significance. The flow-cytometric analysis 
identified a CD3+ CD8− lymphocyte population with high frequency of IL-4-, IL-5-, and 
IL-13-producing cells. No clinical benefit was observed after therapeutic strategies with 
imatinib, interferon-α, cyclosporine-A, and azathioprine. Due to high IL-5 serum levels, an 
intravenous treatment with anti-IL-5 monoclonal antibody mepolizumab (750 mg every 
4 weeks) was started. A reduction in the rate of exacerbation phases/year (10 ± 3 vs 
2 ± 1; p < 0.005), in the eosinophils count both in percentage (28.8 ± 12.8 vs 9.8 ± 3.9; 
p < 0.001) and absolute value (2,737 ± 1,946 vs 782 ± 333; p < 0.001) were observed as 
well as the ECP serum levels (132.7 ± 62.7 vs 21 ± 14.2 μg/l; p < 0.05). The daily dose of 
prednisone was significantly reduced (25 vs 7.5 mg). Any adverse effects were recorded. 
To the best of our knowledge, this case is the first report of the disease successfully 
treated with mepolizumab, and it could represent a novel therapeutic strategy in GS.
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INtRoDUCtIoN
We report the case of a 37-year-old man with a history starting at age 15 of recurrent episodes of 
angioedema of the head, trunk, and limbs, associated with myalgias, fever, hypereosinophilia [during 
an acute phase eosinophils had risen to 6,000/mm3 corresponding to 45% of circulating white cells 
and the eosinophil cationic protein (ECP) had risen to >200 μg/l], and also characterized by oliguria 
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and weight gain (5–7  kg). The patient was being treated with 
high doses of oral steroids during the acute phase (prednisone 
50–75  mg/day), the dose of maintenance being 25  mg/day. In 
October 2008, the patient was referred to our care and, according 
to classification criteria, was diagnosed with Gleich’s syndrome 
(GS). C1-esterase inhibitor levels and functional activity were in 
the normal range. At admission, the hemocromocytometric anal-
ysis showed hypereosinophilia (39% of WBC, 4,600/mmc) and 
increase of ECP (40 μg/l, n.v. <12 μg/l) and serum IgM [1,210 mg/dl 
(n.v. 40–230 mg/dl)], without any other alterations. No mono-
clonal components were identified. Total IgE was 134 kU/l (n.v. 
<85), and specific IgE for Dermatophagoides pteronyssinus 
(5.3 kUA/l; n.v. <0.10) was also observed. IgE for Echinococcus 
and Aspergillus fumigatus was not found. Parasitic infestations 
were excluded by serological tests and stool microscopic examina-
tion. A bone marrow biopsy showed “chronic pattern compatible 
with hypereosinophilic syndrome” while genetic tests to search 
for mutations including Bcr/Abl, JAK2 V617F, c-KIT D816V, and 
FIP1L1-PDGFRA were negative. Using Luminex technology, 
interleukin (IL)-5, CCL2, and CCL11 were repeatedly measured 
in serum during three different acute exacerbations and subse-
quent phases of clinical remissions. We observed higher levels of 
these cytokines during the acute exacerbations than in the clini-
cal remission phases; at remission, values were similar to those 
observed in healthy controls (n = 5) (Figure 1A). As shown in 
Figure 1B, the flow-cytometric analysis of intracellular cytokine 
staining, upon polyclonal stimulation of peripheral lymphocytes 
collected during an exacerbation phase, showed a Th2-skewed 
cytokine profile. In particular, T helper (Th) cells, identified as 
CD3+ CD8− lymphocytes, showed high frequencies of IL-4-, 
IL-5-, and IL-13-producing cells, with normal values of IFN-γ. 
With regard to cytotoxic T cells, CD3+ CD8+ lymphocytes, they 
showed low proportion of IFN-γ-producing elements. In addi-
tion, the FACS analysis of TCR Vβ repertoire does not suggest 
a monoclonal expansion concerning the CD8+, CD4+ T cells, 
and CD3− CD4+ cells. For these latter cells, the analysis was 
performed at intracellular levels (data not shown). However, the 
existence of a very low percentage of monoclonal cell population 
among the CD3−CD4+ T cells cannot be completely excluded.
Previous therapeutic strategies, which had been performed in 
other centers, with imatinib and interferon-α had failed. We then 
proposed a therapeutic regimen with cyclosporine-A (3 mg/kg/
day), as a steroid-sparing drug, but had to stop it after 6 months 
due its clinical inefficacy. We decided to start with azathioprine 
(100 mg/day), but the patient displayed a progressive increase of 
liver enzymes leading to therapy interruption after 2 months. The 
clinical manifestations were then managed with daily treatment 
with oral corticosteroids (25 mg/day) with increase of the dose 
(up to 75 mg/day) during the exacerbation phases.
Taking into account, the high serum levels of IL-5 shown in the 
patient and the role of this cytokine in eosinophil differentiation 
and survival, after obtaining written informed consent from the 
patient and the local Ethical Committee approval, in April 2011 
we started intravenous treatment with anti-IL-5 monoclonal 
antibody mepolizumab (kindly supplied from GlaxoSmithKline) 
750 mg every 4 weeks. After a follow-up period of 5 years, a reduc-
tion in the rate of exacerbation phases/year (10 ± 1.4 vs 2 ± 0.45; 
p  <  0.005) and in the eosinophils count both in percentage 
(28.8 ± 3.6 vs 9.8 ± 1; p < 0.001) and absolute value (2,737 ± 5,536 
vs 782 ± 104; p < 0.005) were observed (Figure 1C). Besides a 
reduction of the frequency of clinical attacks, the treatment with 
mepolizumab allowed a significant decrease of the severity of each 
exacerbation in terms of mean weight gain (5.3 ± 1 vs 1.3 ± 0.4, 
p <  0.0001) and in the daily maintenance dose of prednisone 
(25 vs 7.5 mg). Specifically, all the exacerbations experienced dur-
ing the treatment have required short courses of medium doses of 
steroids (prednisone 15 mg/die for 5 days) to control symptoms. 
Furthermore, a statistically significant reduction of ECP serum 
levels (132.7 ± 62.7 vs 21 ± 14.2 μg/l; p < 0.05) measured in sam-
ples collected at exacerbations before mepolizumab treatment 
and during the patients’ visits at follow-up after the beginning 
of therapy.
Moreover, the frequency of IFN-γ-producing CD4+ T  cells 
following polyclonal stimulation remained unchanged 10 months 
after the beginning of mepolizumab therapy, whereas the fre-
quency of IL-5, IL-13 and in particular IL-4, producing CD4+ 
T  cells was slightly reduced. With regard to CD8+ T  lympho-
cytes, a clear increase of IFN-γ-producing cells was observed after 
therapy (Figure S1 in Supplementary Material).
The patient is still under treatment, and until now he has been 
submitted to a total number of 64 administrations, without any 
adverse effects. The patient has provided the written informed 
consent for the publication.
BaCKGRoUND
Gleich’s syndrome is a disorder characterized by recurrent episodes 
of angioedema, increase in body weight, fever, hypereosinophilia, 
and elevated serum IgM (1). Its exact etiology remains unclear, 
although it has been proposed that Th cells play a role by producing 
greater amounts of cytokines including granulocyte macrophage-
colony-stimulating factor (GM-CSF), IL-3, IL-5, and IL-6 (2, 3). 
A specific treatment for GS is currently lacking, and the only 
strategy is the administration of a high dose of steroids dur-
ing the acute phases of the disease. Recently, the availability 
of mepolizumab, a fully humanized IgG1 antibody specific for 
IL-5, has been approved for the treatment of severe eosinophilic 
asthma as well as eosinophilic granulomatosis polyangiitis (4, 5). 
Mepolizumab, administered intravenously at 750  mg every 
4  weeks, has been demonstrated to be safe and effective as a 
corticosteroid-sparing agent in patients suffering from FIP1L1-
PDGFRA negative hypereosinophilic syndrome (HES). No 
significant adverse events were observed in treated patients (6, 7).
DIsCUssIoN
To the best of our knowledge, this case is the first report of GS 
successfully treated with mepolizumab, even if the drug does 
not completely deplete eosinophils. IL-5 is a critical regulator 
of eosinophils and a therapeutic target in clinical conditions in 
which eosinophils are the main pathogenic cells, such as in HES. 
The demonstration of high serum levels of IL-5 in our patient 
during the exacerbation phases of the disease is in agreement with 
the therapeutic choice of using an anti-IL-5 antibody. Although a 
FIGURe 1 | (a) Cytokines and chemokines serum levels during acute exacerbations and clinical remissions in the patient. Healthy donors’ values are reported as 
control. Mean values ± SEM are reported. (B) Cytofluorimetric analysis of cytokines production of peripheral blood T lymphocytes (CD3 gated) before treatment 
(peripheral blood mononuclear cells were polyclonal stimulated for 6 h in the presence of phorbol myristate acetate plus ionomycin, in the last 4 h brefeldin A was 
added to inhibit cytokines exocytosis. After stimulation, cells were fixed in formaldehyde, and cell membranes were permeabilized with saponin to permit the staining 
of intracellular cytokines with the appropriate fluorochrome-conjugated monoclonal antibodies. Samples were evaluated by BLSRDII flow-cytometer (BD-
Biosciences, San Jose, CA, USA). At least 104 elements were acquired for each sample and analyzed by FacsDiva BD software. (C) Exacerbation/year and blood 
eosinophils (absolute value and percentage) before and after the treatment. Mean values ± SEM are reported.
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clonal expansion of CD4+ T cells has been shown in a proportion 
of patients suffering from GS (8), the production of high amounts 
of IL-5 can be sustained by a non-clonal T cell population, as in 
our case of GS. The therapeutic effect of mepolizumab is related 
to its ability to indirectly reduce eosinophil count; however, in 
our case, we observed the persistence of low levels of circulating 
eosinophils. These data likely reflect: (i) the incomplete neu-
tralization of IL-5 which was overproduced and (ii) the presence 
of alternative pathways for eosinophil maturation and survival 
such as those induced by GM-CSF and IL-3 (9). On the other 
hand, mepolizumab is not expected to exert inhibitory effects 
on IL-5-producing T cells described in our case, and the small 
difference in the IL-5 expression after treatment does not allow 
us to draw any conclusions. Given that GS, like the other forms of 
HES, is a chronic disease, mepolizumab must be used over a long 
period; for this reason, and considering the prolonged eosinophil 
depletion, its safety profile must be confirmed. In experimental 
models, the eosinophil-deficient mice appear to display no overt 
changes in health, fecundity, ability to nurse, and vitality relative 
to normal mice (10). Concerning human experience, patients 
lacking eosinophils do not display any abnormalities related 
to eosinophil reduction (11). Furthermore, HES patients who 
have received mepolizumab for several years and who have not 
developed any specific set of adverse events confirm the safety of 
this monoclonal antibody (7).
In conclusion, mepolizumab has proved effective and safe in 
our patient and could represent a novel therapeutic strategy in GS 
even though additional studies are needed.
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